(Read More: See the Day's Top Percentage Winners & Losers)
MetroPCS Communications - MetroPCS received what Deutsche Telekom calls its "best and final offer" to merge its T-Mobile USA unit with MetroPCS. The new deal sweetens the prior agreement by reducing the amount of debt the combined company would hold by $3.8 billion.
Costco Wholesale - Costco reported a four percent rise in same-store sales for March, below analysts' forecasts of a 5.2 percent rise. Costco was hurt by lower fuel prices and a stronger dollar.
Fortinet - Fortinet is predicting current quarter profit of $0.10 to $0.12 per share, below its prior estimate of $0.11 to $0.12 a share and Street forecasts of $0.12 a share. The maker of network security products has been hurt by cautious customer spending and a delay in closing deals.
Zumiez - The retailer reported a March same-store sales increase of 2.1 percent, much better than analysts' forecasts of a 7.5 percent drop from a year earlier. Zumiez specializes in snowboarding and outdoor apparel.
Hewlett-Packard, Dell - New IDC data shows personal computer sales were down 14 percent in the first quarter compared to a year earlier.
International Paper - Third Point's Daniel Loeb added to his position in IP during the first quarter. His quarterly investment letter highlights a "compelling case" to own IP shares.
Protective Life - The Alabama-based insurer is buying a portfolio of U.S. policies from France's AXA for $1.1 billion. AXA is the owner of long-time U.S. insurance brand Mony, which it bought in 2004.
Microsoft - Micrsoft is developing a new line of its Surface tablets, according to The Wall Street Journal. That includes a new 7-inch version, as it tries to keep up with Google and Apple in the smaller tablet market. Separately, Microsoft has been downgraded to "sell" from "neutral" at Goldman Sachs, while Nomura has cut its rating to "neutral" from "buy." The Nomura report cites sluggish adoption of Windows 8, among other factors.
Limited Brands - The retailer reported March same-store sales increased 3 percent, better than the unchanged sales estimate of analysts surveyed by Thomson Reuters.
Quest Diagnostics - Goldman Sachs upgraded the medical laboratory operator's stock to "buy" from "neutral," citing improved fundamentals and new management.
NCR - JPMorgan Chase added NCR's stock to its "Focus List," saying recent acquisitions will be "transformational" for the company and play a significant role in increasing profit margins.
Acadia Pharmaceuticals - The drugmaker said it has sufficient data to file a New Drug Application for its "Pimavanserin" Parkinson's Disease treatment, making another phase-3 study unnecessary.